Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for roughly 10 billion dollars in cash, paying 85 dollars per share, a premium of 102 percent over the target's most recent closing price. The agreement, announced this week, ranks among the largest biotech acquisitions of the year and sent Crinetics shares roughly doubling as investors digested the terms.
Boston-based Vertex, best known for its dominant franchise in cystic fibrosis treatments, has been seeking to broaden its portfolio beyond its core business. The Crinetics purchase carries the company into endocrinology, a field covering hormone-related conditions, and comes amid a booming year for pharmaceutical mergers and acquisitions as large drugmakers race to refill their pipelines.
The centerpiece of the deal is Palsonify, a Crinetics drug launched last year that treats acromegaly, a rare endocrine disorder caused by excess growth hormone. Alongside the commercial product, Vertex gains a series of drug candidates that analysts believe hold blockbuster potential if they win regulatory approval, with industry observers describing the endocrinology market as a largely untapped opportunity.
Vertex values the transaction at about 8.8 billion dollars net of the cash it expects to acquire with Crinetics, and the company projects the deal will begin adding to adjusted operating income in 2029. The boards of both companies have approved the agreement, which is expected to close in the third quarter of the year, subject to regulatory clearance and shareholder approval.
Markets reacted swiftly to the announcement. Crinetics stock jumped about 101 percent following the news, closing in on the offer price, while analysts noted that the hefty premium reflects intensifying competition among large biotech firms for companies with approved products and late-stage pipelines. The deal follows a series of multibillion-dollar transactions that have made 2026 one of the busiest years for biotech deal-making in recent memory.
Attention now turns to the regulatory review and to whether other bidders or further consolidation will follow. Industry analysts expect the pace of acquisitions to continue through the second half of the year, as established drugmakers deploy large cash reserves to secure new sources of growth before key patents expire.
Comments